Drugs / Mavodelpar
Mavodelpar
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04226274 | Dec 2019 → Oct 2021 | glycogen storage disease V | Reneo Pharma Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03862846 | May 2019 → Apr 2020 | pure mitochondrial myopathy | Reneo Pharma Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT03833128 | Apr 2019 → Jan 2022 | disorder of fatty acid oxidation and ketogenesis | Reneo Pharma Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01524406 | Jan 2012 → Jun 2013 | muscular atrophy | High Point Pharmaceuticals, LLC. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04535609 | May 2021 → Sep 2023 | pure mitochondrial myopathy | Reneo Pharma Ltd | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05267574 | Feb 2022 → Dec 2023 | pure mitochondrial myopathy | Reneo Pharma Ltd | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mavodelpar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04535609 ↗ |
| Known as | HPP593 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01524406 ↗ |
| Known as | MAVODELPAR SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314562 ↗ |
| Known as | NN-0606 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314562 ↗ |
| Known as | REN-001 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314562 ↗ |
| Known as | REN001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05267574 ↗ |
| Known as | REN001 sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314562 ↗ |
| Modality | Small molecule | — CHEMBL5314562 ↗ |
| Route | Oral | “Oral, twice a day.” NCT01524406 ↗ |